Assessments of outcome in haemophilia - what is the added value of QoL tools?

Haemophilia

Volumn 21, Issue 4, 2015, Pages 430-435

  van den Berg, H M ^a   Feldman, B M ^b,c   Fischer, K ^a,d   Blanchette, V ^b,e   Poonnoose, P ^f   Srivastava, A ^f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF TORONTO   (Canada)

^f CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Haemophilia; Haemophilia health joint score; Health related quality of life; Outcome assessment

Indexed keywords

ANNUAL BLEEDING RATE; BLEEDING; FUNCTIONAL INDEPENDENCE SCORE IN HEMOPHILIA; FUNCTIONAL STATUS ASSESSMENT; HEALTH CARE ACCESS; HEMATOLOGICAL PARAMETERS; HEMOPHILIA; HEMOPHILIA ACTIVITIES LIST; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYSTEM; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; REVIEW; HEMOPHILIA A; JOINT; MUSCULOSKELETAL DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; JOINTS; MUSCULOSKELETAL DISEASES; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 84931955321     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12731     Document Type: Review

References (30)

1. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic therapy in severe haemeophilia A and B. J Int Med 1992; 1: 25-32.
2. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
4. Fischer K, Steen Carlsson K, Petrini P et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-36.
5. World Health Organization. International Classification of Functioning, Disability and Health (ICF). Geneva: WHO. Available at http://www.who.int/classifications/icf/en/. 2001.
6. World Health Organization. International Classification of Functioning, Disability and Health, Children and Youth Version. Geneva: WHO. Available at http://www.who.int/classifications/icf/en/. 2007.
7. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002; 43: 528-32.
8. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935-9.
9. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Haematol 1993; 30: 3-6.
10. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
11. Feldman BM, Funk SM, Bergstrom BM et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63: 223-30.
12. Groen W, van der Net J, Bos K et al. Joint health and functional ability in children who receive intensive replacement therapy. Haemophilia 2011; 17: 783-90.
13. Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of hameophilic arthropathy. Haemophilia 2004; 10: 383-9.
14. Keshava S, Gibikote S, Mohanta A, Doria AS. Refinement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia 2009; 15: 1168-71.
15. Poonnoose PM, Thomas R, Keshava SN et al. Psychometric analysis of the functional independence score in haemophilia (FISH). Haemophilia 2007; 13: 620-6.
16. van Genderen FR, van Meeteren NL, van der Bom JG et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10: 565-71.
17. Groen WG, van der Net J, Helders PJ et al. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (pedhal). Haemophilia 2010; 16: 281-9.
18. Von Mackensen S, Bullinger M; Haemo-QoL Group. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10(Suppl. 1): 17-25.
19. Young NL, Bradley CS, Blanchette V et al. Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT). Haemophilia 2004; 10(Suppl. 1): 34-43.
20. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992; 30: 473-83.
21. Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res 2003; 12: 363-71.
22. Arranz P, Remor E, Quintana M, Villar A, Díaz JL, Moreno M. Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia. Haemophilia 2004; 10: 376-82.
23. Remor E, Young NL, Von Mackensen S, Lopatina EG. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia 2004; 10(Suppl. 4): 30-4.
24. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19: e239-47.
25. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88: 329-35.
26. Krasuska M, Riva S, Fava L, Von Mackensen S, Bullinger M. Linking quality-of-life measures using the International Classification of Functioning, Disability and Health and the International Classification of Functioning, Disability and Health-Children and Youth Version in chronic health conditions: the example of young people with hemophilia. Am J Phys Med Rehabil 2012; 91(13 Suppl 1): S74-83.
27. Gringeri A, Lundin B, Von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
28. European Medicine Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products; EMEA/CHMP/EWP139391/2004. London: EMA, 2004 www.emea.eu.int.
29. Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD: FDA, 2009 www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
30. Buchbinder D, Ragni MV. What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia? Hematology Am Soc Hematol Educ Program 2013; 2013: 52-5.